After a riveting few days at TechCrunch Disrupt 2024, our CEO Piotr Byrski will be at GenAI Summit Silicon Valley 2024 today! Next week, Piotr will be in Boston with Mike Monka to attend Discovery US 2024. #GenAISummit #TCDisrupt2024 Have questions about our new custom synthesis offerings? Reach out to our team!
molecule.one
Produkcja wyrobów farmaceutycznych
Warsaw, Mazowieckie 2738 obserwujących
Make medicines faster.
Informacje
We leverage AI to design novel chemical syntheses within seconds.
- Witryna
-
https://molecule.one
Link zewnętrzny organizacji molecule.one
- Branża
- Produkcja wyrobów farmaceutycznych
- Wielkość firmy
- 11–50 pracowników
- Siedziba główna
- Warsaw, Mazowieckie
- Rodzaj
- Spółka prywatna
- Data założenia
- 2016
Lokalizacje
-
Główna
Senatorska
18a
Warsaw, Mazowieckie 00-082, PL
Pracownicy molecule.one
-
Paweł Łaskarzewski
Keynote Speaker | Web3 and AI Strategist | FinTech, Banking, Blockchain
-
Dominik Andrzejczuk
Founder & Board Director @ The Intermarium Foundation
-
Lukasz Wegrzyn
Partner @ Osborne Clarke Poland, Head of IT & Data
-
Weronika Czyżyk-Węgrzyn
Attorney-at-law, In-House Lawyer at Benefit Systems S.A.
Aktualizacje
-
molecule.one focus has always been on our data-generation capabilities, and we have begun selling compounds! Our synthesis team is aided by our proprietary technologies and automated workflows, allowing us to provide hard-to-synthesize compounds at a cheaper rate with record delivery times. Find more details at our new website: https://molecule.one/
-
We’re currently hiring and looking for talented individuals to join our team! If you're seeking new challenges in a dynamic environment where you can grow your skills and passions, we’d love to hear from you! Find more details here: https://lnkd.in/dixiMxEw Join us and help shape the future! 💡 #hiring #jobopportunity #careers #recruitment
-
Molecule.one's CEO, Piotr Byrski, will be speaking on the use of AI to accelerate drug discovery at #PHASE2024 tomorrow at 3pm. Catch him in person at Giełda Papierów Wartościowych at ul. Ksiażęca 4 in Warsaw or via the livestream: https://lnkd.in/ebXW5n7z
#PHASE2024 | 27-29.08 | #Biznes #AI rozgrzała wyobraźnię inwestorów na całym świecie. Jednocześnie sieć rozśmieszają memy o procesach due dilligence start-up'ów AI. Sam rynek AI #drugdiscovery ma rosnąć do końca dekady w średniorocznym tempie ponad 50%. Opracowywane technologie mogą zmienić oblicze #biotech. O tym gdzie szukać wartości w tego typu projektach, porozmawiamy z top-menedżerami śmietanki polskich spółek rozwijających zastosowania sztucznej inteligencji w procesach odkrywania leków. 🗓 28.08 / 15:00 AI Drug Discovery: gdzie szukać wartości? 🎙 Anna Pietruszka / CK LEGAL Chabasiewicz Kowalska i Wspólnicy ▶ Piotr Byrski / Molecule.one ▶ Janusz Homa / Ardigen ▶ Kinga Matuła / QurieGen ▶ Greg, Grzegorz Warzecha / Genotic Inne panele: https://lnkd.in/d_jgUeb2 Udział bezpłatny. Zarejestruj się na www.pha-se.pl 🤝 on-site & 📺 on-line | 💬 PL>EN & EN>PL #biotech #biotechnologiamedyczna #deeptech #inwestycje #biznes #gospodarka #technologie #nauka #innowacje #medycyna #zdrowie
-
Thank you, Discovery | Charles River, for trusting Molecule.one's solution with providing synthetic pathways and synthesizability scores to accelerate your discovery pipelines. With access to the world's largest database of chemical reactions, M1 RetroScore powered by CAS accurately predicts the success likelihood for compound synthesis, allowing for cost & time savings. Let us deliver these results for you: contact Mike Monka at m.monka@molecule.one to improve your synthesis efficiency.
Fast triage of large numbers of compounds for synthetic accessibility is critical for today’s AI processes, whilst tools that support the rapid identification of viable routes for challenging target compounds or alternative routes for scale-up chemistry can help to accelerate drug programs. By partnering with Charles River, clients gain access to insights generated by Molecule One’s “M1 RetroScore powered by CAS”, enabling our teams to generate a score for synthetic accessibility for thousands of compounds an hour while also supporting medicinal and scale-up chemists in efficiently identifying the best routes to new chemical entities Learn more about Charles River’s #drugdiscovery chemistry services: https://okt.to/vOLmI2
Discovery Chemistry Services
-
Accelerate Drug Discovery at BIO2024 with Molecule.one's AI! #BIO2024 Excited to be at #BIO2024 showcasing Molecule.one's AI-powered solutions for pharmaceutical chemists! Our flagship product, M1 RetroScore powered by CAS leverages the world's biggest database of chemical reactions to predict the likelihood of success for drug compound synthesis. Connect with us at BIO 2024! Visit us at the Polish Investment Agency Booth (4049) or schedule a meeting with our CEO, Piotr Byrski: https://lnkd.in/d4Efjk2V #MoleculeOne #AI #DrugDiscovery #BIO2024 #chemistry
#BIO2024: day 2 My focus at BIO this year? Help you save up to 5x in cost and 2.5x in time needed to synthesize new compounds. How? M1 RetroScore powered by CAS helps you prioritize molecules that are easy to synthesize, view their synthesis pathways, find cheaper analogs. Trained on the CAS Content Collection: probably the most knowledgeable source on planet Earth for chemical reactions. Meet me at the Polish Investment Agency Booth (no. 4049). Let's connect and discuss how Molecule.one can supercharge your small molecules discovery pipeline. You can schedule a meeting with me using this link: https://lnkd.in/d-Y7EEe3 #MoleculeOne #AI #DrugDiscovery #retrosynthesis #syntheticaccessibility
-
We are excited to announce that Molecule.one has secured funding from the EU for the project "Development of machine learning algorithms and an IT system based on them to suggest chemical reaction conditions for key reaction classes". Predicting the optimal conditions for chemical reactions poses a significant challenge for chemists, often resulting in valuable time lost on unsuccessful experiments and impeding the pace of drug development. At present, the market lacks a commercial product capable of precisely forecasting these reaction conditions. Our project aims to address this gap by developing AI-powered models and software designed to streamline the planning of full chemical synthesis pathways including reaction conditions. We intend to carry out more than 800,000 chemical reactions across eight distinct reaction classes, creating what we believe to be the most extensive dataset of its kind to date. Our innovative product is specifically geared towards meeting the needs of pharmaceutical companies, promising to revolutionize their research and development processes. Project Value: 20 968 771.16 PLN (5 256 904 USD) EU Funds Contribution: 14 199 877.80 PLN The funding agreement No. FENG.01.01-IP.02-0907/23 was signed on 20th December 2023. #EUfunds #EuropeanFunds More information at: https://lnkd.in/dTwtWsx5 or https://lnkd.in/d9rHbBS
-
We are delighted to be part of this year’s ACS Spring conference in New Orleans. If you’re present and interested in learning how we integrate HTE chemistry and Machine Learning, we invite you to attend Filip Ulatowski talk on Wednesday, March 20th. #acs #acsspring2024 #moleculeone
-
As 2023 slowly comes to a conclusion, we would like to wish you a Merry Christmas and Happy Holidays, filled with warmth and love. May the new year be kind and full of good moments for all of you! Molecule.one team
-
Exciting news! The Molecule.one team is heading to #NeurIPS 2023 in New Orleans, a leading annual conference in the field of machine learning and artificial intelligence. Our team (Mikołaj Sacha, Piotr Kozakowski, Michał Sadowski, Jan Busz) will be presenting “Molecule-Edit Templates for Efficient and Accurate Retrosynthesis Prediction” at two workshops: ➡ ML4Molecules: 📅 December 8, 2023 Online: https://lnkd.in/gUN8GVDs ➡ AI4Science: 📅 December 16, 2023 In-person: https://lnkd.in/gtuYTDCh Hope to see you there! #NeurIPS2023 #ML4Molecules #AI4Science